CA-PERSONALIS
18.2.2020 22:07:10 CET | Business Wire | Press release
Personalis, Inc. (Nasdaq: PSNL), a leader in advanced genomics for cancer, today announced that the company will present at the Biomarkers Series UK 2020 conference in Manchester, UK, February 19-20.
The presentation , titled “Maximizing Immunotherapy Biomarker Discovery with an Advanced Tumor Immunogenomics Platform,” will describe the Personalis universal cancer immunogenomics platform, ImmunoID NeXT ™. Erin Newburn, MS, PhD, will present for Personalis. Dr. Newburn will provide an overview of how the platform can be used to explore critical immunotherapy-related resistance mechanisms and novel composite biomarkers of response utilizing analytics including human leukocyte antigen (HLA) typing and HLA loss of heterozygosity (LOH), neoantigen prediction and load, immune repertoire characterization, oncoviral detection, as well as the evaluation of tumor mutational burden (TMB) and microsatellite instability (MSI) status.
ImmunoID NeXT ™ is the first platform to enable comprehensive analysis of both a tumor and its immune microenvironment from a single sample. The platform can be used to investigate the key tumor- and immune-related areas of cancer biology, consolidating multiple oncology biomarker assays into one and maximizing the biological information that can be generated from a single tumor specimen.
Personalis will also be exhibiting during the conference (Exhibit #38). Representatives will be available to answer questions about the company’s cancer immunogenomics capabilities.
About Personalis, Inc.
Personalis, Inc. is a growing cancer genomics company transforming the development of next-generation therapies by providing more comprehensive molecular data about each patient’s cancer and immune response. The company’s NeXT™ Platform is designed to adapt to the complex and evolving understanding of cancer, providing its biopharmaceutical customers with information on all of the approximately 20,000 human genes, together with the immune system, from a single tissue sample. Personalis also provides genomic information to the VA Million Veterans Program as part of their goal to sequence over a million veteran genomes. The Personalis Clinical Laboratory is GxP aligned as well as CLIA’88-certified and CAP-accredited. For more information, please visit www.personalis.com and follow Personalis on Twitter (@PersonalisInc ).
View source version on businesswire.com: https://www.businesswire.com/news/home/20200218006062/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Golub Capital Expands Broadly Syndicated Loan CLO Business to Europe10.2.2026 15:00:00 CET | Press release
The Firm brings credit-first, top performing platform to meet demand from European partnersIndustry veteran Tyler Wallace appointed to lead strategy in London Today, Golub Capital (“the Firm”) announced the expansion of its BSL CLO strategy to Europe and the appointment of Tyler Wallace as Managing Director, European Broadly Syndicated Loans. Wallace brings more than 20 years of leading credit experience to the Firm and most recently was a Managing Director and Portfolio Manager of CLOs at Fair Oaks Capital in London. “This is a natural expansion for us,” said Scott Morrison, Head of BSL at Golub Capital. “The expansion builds on our market-leading U.S. CLO platform and strengthens our ability to deliver comprehensive financing solutions to partners across Europe.” Said Tyler Wallace, “Golub Capital has an exceptional BSL track record. I am excited to lead this next chapter and bring the Firm’s capabilities to partners in the region.” As of December 31, 2025, Golub Capital manages over
Draslovka and Avathon Partner to Deliver AI-Powered Solutions for Mining Through Autonomy, MetOptima and Blue Cube Combined Offering10.2.2026 15:00:00 CET | Press release
Draslovka a.s. (“Draslovka”), a global innovator in sustainable chemical technologies and AI‑enabled services for the mining sector, and Avathon, the leader in Autonomy for Operations, today announced a strategic commercial partnership to accelerate the adoption of intelligent, autonomous, and data‑driven operations across the global mining industry. The partnership provides a breakthrough solution that combines Draslovka’s real‑time mineral and slurry monitoring technologies—delivered through its world class Blue Cube on‑stream mineralogical sensors—and MetOptima advanced metallurgical optimization AI engine, with the Avathon Autonomy Platform, a scalable industrial‑AI environment that enhances operational performance, automating decisions, and orchestrating complex operations across sites. Under the agreement, Draslovka and Avathon will collaborate closely on go-to-market initiatives, jointly commercializing and cross‑selling the combined offering. The combined Draslovka‑Avathon offe
Telekom Srbija Group Wins Telecom Deal of the Year Award for Landmark $900M Eurobond10.2.2026 14:53:00 CET | Press release
Recognition at the TMT Finance Awards EMEA 2026 for Telekom Srbija Group’s international corporate Eurobond demonstrates the company’s leadership in global telecom finance Telekom Srbija Group has been honoured with the Europe Telecom Deal of the Year award at the prestigious TMT Finance Awards EMEA 2026, recognising excellence in telecom financing. The award was given for its US$900 million corporate Eurobond, listed on Euronext Dublin. The award celebrates outstanding dealmaking in the telecom sector across Europe, the Middle East and Africa. The distinguished accolade highlights Telekom Srbija’s strategic success in executing a high-profile international financial transaction that strengthened investor confidence and expanded the company’s footprint in capital markets. This marks a significant milestone in Telekom Srbija Group’s continued growth and global recognition. Vladimir Lučić, CEO of Telekom Srbija Group, said: “We are incredibly proud that our Eurobond has been recognised a
Intuit Mailchimp Unlocks a New Era of Profitable Ecommerce Marketing with Advanced, Data-Driven Capabilities10.2.2026 14:30:00 CET | Press release
Built to deliver ROI for less cost, Mailchimp now combines unified data with powerful automation across email and messagingProduct innovations available in 185 countries and territories across North America, Latin America, EMEA and APACSMS launching in 34 new markets across EMEA including Belgium, Sweden, Denmark, Norway, Finland, Portugal, Greece, Poland and more Intuit Inc. (Nasdaq: INTU), the global financial technology platform that makes Intuit TurboTax, Credit Karma, QuickBooks, and Mailchimp, today announced a set of Mailchimp product innovations that unlock profitable growth for ecommerce businesses. Powered by the Intuit platform, the enhancements include more ways for merchants to connect their data and activate omnichannel campaigns driving up to 30x ROI for ecommerce customers1 without the added price or complexity. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260210726144/en/ Built to deliver ROI for less cost
ILiAD Biotechnologies Announces $115M Oversubscribed Series B Financing to Advance BPZE1 Pertussis Vaccine10.2.2026 14:00:00 CET | Press release
Financing round led by RA Capital ManagementProceeds to support Phase 3 development of BPZE1 with pivotal study to begin in 2026 ILiAD Biotechnologies, Inc. (ILiAD), an advanced clinical stage biotech company focused on the prevention and treatment of disease caused by Bordetella pertussis, today announced the successful closing of an oversubscribed $115 million Series B financing. The financing was led by RA Capital Management with participation from new investors Janus Henderson Investors and BNP Paribas Asset Management Alts, as well as existing investors including a multi-national pharmaceutical company and AI Life Sciences. As part of the financing, Mario Barro, Ph.D., Head of Infectious Diseases at RA Capital Management has joined ILiAD’s Board of Directors. Proceeds from the Series B financing will support the advancement of ILiAD’s next generation pertussis vaccine candidate, BPZE1. Inducing both systemic and mucosal immunity, BPZE1 is a live attenuated intranasal pertussis vac
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom